Clinical Faculty: Robert C. Flanigan, M.D.
Professor and Albert J. Speh, Jr.,
and Claire R. Speh Chair in Urology

Subspecialty/Clinical Expertise Board Certification Available to See Patients Appointment/Contact Info Education/Training Professional Organizations Awards/Distinctions Publications/Presentations Research Initiatives

Subspecialty/Clinical Expertise: Urologic Oncology, Renal Transplantation

Board Certification:

• American Board of Surgery; certified 1978, recertified 1988, recertified 1998

• American Board of Urology; certified 1980

Available to See Patients at: Cardinal Bernardin Cancer Center (Building 13 on the LUMC campus map) and Oakbrook Terrace

To Schedule an Appointment: Call (888) LUHS-888
Fax: (708) 216-8472

Back to top

Education/Training

Undergraduate: College of Wooster (Wooster, OH); graduated with B.A. in chemistry, 1964-1968

Medical School: Case Western Reserve University (Cleveland, OH); M.D., 1968-1972

Residency: Resident, Surgery and Urology; Case Western Reserve University (Cleveland, OH); 1972-1978

Fellowship: Clinical Fellow in Urologic Oncology; American Cancer Society; University of Kentucky; 1980-1982

Back to top

Professional Organizations:

• AUA Education Committee; 1999-present
  

• Pfizer/American Urology Association; Visiting Professor in Urology, Academy Adv. Bd.; 1999

• Board of Trustees, American Board of Urology; 1999

• European Association of Urology; 1999

• Search Committee - Dean; Stritch School of Medicine; 1999

• Chairman, CaP Cure Award Committee; AUA; 1997-1999

• Executive Management Group, Loyola University; 1995-present
  

• Health Care Capital Budget Committee, Loyola University (1995-present)
  

• Vice President, Loyola Medical Practice Foundation; 1995-present

• Consultant Evaluator for Urology American Medico-Legal Foundation; 1995-present

• Medical Advisory Board, National Kidney Cancer Association; 1994-present

• Oral Examiner, American Board of Urology; 1994-present

• Graduate Medical Education Committee, American Urological Association; 1994-present

• American Association of Genito-Urinary Surgeons; member, 1993-present; Membership Committee, 1999-present; Nominating Committee, 1999

• American Association of Clinical Urologists; 1993

• Internal Advisory Committee, Loyola University Oncology Institute; 1993-present

• Medical Advisory Board, National Kidney Cancer Association; 1993-present

• Society of Urologic Oncology; member, 1992-present; Chairman Nominating Committee, 1996; Long Range Planning Committee, 1997-present

• Program Abstract Committee, American Urology Association; 1992-present

• Urology Research Committee, National Kidney Foundation; 1992-present

• Graduate Medical Education Committee, Long-range Planning Committee; Loyola University; 1991-present

• Credentials Committee; Loyola; 1991-present

• Chairman, Membership Committee, Society of Urologic Oncology, 1991-present; Exec. Committee, 1991-present

• American Society of Transplant Surgeons; 1990-present

• Illinois State Urological Society; member, 1990-present; Executive Committee, 1996-present

• American Society of Clinical Oncology; 1989

• Society of Pelvic Surgeons; member, 1989; Nominating Committee, 1996; Councilor, 1996; Membership Committee, 1997-2001; Education Committee, 1999-present

• Chicago Urological Society; Executive Committee, 1989-present; President, 1997-1998

• Society for Basic Urologic Research; 1988

• Principal Investigator (Loyola) Urological Cancer Outreach Program; 1988-present

• Executive Committee, Medical Advisory Board; National Kidney Foundation of Illinois; 1987-present

• National Urologic Forum; member, 1986-present; Secretary-Treasurer, 1992-1994; President, 1994-1995

• Chicago Urological Society; member, 1986-present; Secretary-Treasurer, 1995; Vice-President, 1996

• Executive Faculty Committee, Loyola University; 1986-present

• Multi-modality Tumor Committee Loyola University; 1986-present
  

• Clinical Executive Board, Hines VA Medical Center; 1986-present
  

• Medical Council, Stritch School of Medicine; 1986-present

• Societe Internationale d'Urologie; 1985-present

• Society of Surgical Oncology; 1985-present

• Urologic Society for Transplantation and Vascular Surgery; 1985-present

• Sigma XI; 1984-present

• Central Surgical Association; 1983-present

• Fellow, American College of Surgeons; 1983-present

• American Urologic Association; member, 1982; GME Committee, 1995-1998; Education Committee, 1999-present; Program Committee, 1994-present; Socio-Economic Forum, 1999

• North Central Section AUA; member, 1982-present; Alternate rep. from Illinois and Exec. Committee, 1998

• American Medical Association; 1981-present

• Society of University Urologists; member, 1981; Executive Committee, 1992-present; Secretary-Treasurer, 1997

Back to top

Awards/Distinctions:

• Who's Who in Science and Engineering; 2000

• National Registry of Who's Who; 2000

• How To Find The Best Doctors, Castle Connolly; 1999

• Research Board of Adv., Am Biography Institute; 1999

• Who's Who in the World; 1998, 1999

• Chicago's Top Doctors, Chicago magazine; 1998

• American Biographical Institute, Res. Bd. Of Gov.; 1998

• International Man of the Year (IBC); 1997

• Lima City Schools Distinguished Hall of Fame; 1996

• Cardinals' Medallion (Archdiocese of Chicago); 1995

• Who's Who in North America; 1995, 1998, 1999, 2000

• International Who's Who in Medicine; 1994, 1995, 1996, 1997, 1998, 1999

• The Best Doctors in America; 1993, 1994, 1995, 1996, 1997, 1998, 1999

Back to top

Publications/Presentations

Perform a customized PubMed literature search on Dr. Flanigan.

Selected Articles:

• Bahkos, R., Shankey, T.V., Flanigan, R.C., Fisher, S., Wojcik, E.: Comparative Analysis of DNA Flow Cytometry and Cytology of Bladder Barbotages - Review of Discordant Cases. In press Cytopathology.

• Catalona, W.J., Partin, A.W., Slawin, K.M., Naughton, C.K., Brawer, M.K., Flanigan, R.C., Richie, J.P., Patel, A., Walsh, P.C., Scardino, P.T., Lange, P.H., deKernion, J.B., Southwick, P.C., Loveland, K.G., Parton, R.E., Gasior, G.H.: Comparing the use of Percentage of Free PSA in Black and White Men for Detection and Staging of Prostate Cancer: A Prospective Multicenter Trial. Accepted J.Urol.

• Lobel, B., Abbou, C.C., Branoi, M.A., Flanigan, R.C., Kameyana, S., Orikara, S., MacCaffrey, J., Tachibaha, M.: Guidelines for Diagnosis, Treatment, and Follow-up of Bladder Cancer. The Influence of Prognostic Factors. The Significance of Random Biopsies. Proc. International Consensus Conference on Bladder Cancer (Tokyo, Japan). Urol. Oncol. 4:94-105, 1999

• Figlin, R.A., Thompson, J.A., Bukowski, R.M., Vogelzang, N.J., Novick, A.C. et al (RCF Appendix) Multicenter, Randomized, Phase III Trial of CD8+ Tumor-Infiltrating Lymphocytes in Combination With Recombinant Interleukin-2 in Metastatic Renal Cell Carcinoma J.Clinical Oncol. 17:2521-2529, 1999

• Flanigan, R.C.: Improving Prostate Cancer Detection Through the Use of Free PSA Testing. Federal Practitioner 16:42-44, 1999.

• Clark, J.I., Gaynor, E.R., Martone, B., Flanigan, R.C., Waters, W.B., Sosman, JA: Daily Subcutaneous Ultra-Low Dose Interleukin-2 with Daily Low Dose Alpha-Interferon in Patients with Advanced Renal Cell Carcinoma. Clinical Cancer Research 5:2374-2380, 1999

• Southwick, P.C., Catalona, W.J., Parton, A.W., Slawin, K.M., Brawer, M.K., Flanigan, R.C., Patel, A., Richie, JP, deKernion, J.B., Walsh, P.C., Scardino, PT, Lange, P.H., Gasior, C.H., Parson, RE, Loveland, K.G.: Prediction of Post-Radical Prostatectomy Pathology in Stage T1c Prostate Cancer with Percent Free Prostate Specific Antigen: A Prospective Clinical Trial. J.Urol.162:1346-1351, 1999.

• Flanigan, R.C.. Diagnosis and Staging of Prostate Cancer (editorial comment). J.Urol 160(2):437-42, 1998.

• Salomon, C.G., Kalbhen, C.L., Dudiak, C.M., Olson, M.D., Flisak, M.E., Flanigan, R.C.: Transrectal Ultrasound (TRUS) of the Prostate After Cryosurgical Ablation. Radiology, 206:533-538, 1998.

• Koeneman, K.S., Pan, C.X., Jin, J.K., Pyle, J.M., Flanigan, R.C., Shankey, TV, Diaz, M.O.: Telomerase Activity and DNA Ploidy in Prostatic Intraepithelial Neoplasia (PIN). J. Urol. 160:1533-39, 1998.

• Stevens, R.A., Mikat-Stevens, M., Flanigan, R.C., Furry, P., Sheikh, T., Frey, K., Olson, M., Waters, W.B., Kleinman, B.: Does the Choice of Anesthetic Technique Affect the Recovery of Bowel Function After Radical Prostatectomy? Urology. 52:213-218, 1998.

• Manion, S.P., Waters, W.B., Flanigan, R.C.: Efficacy of Retrograde Stentograms Following Cystectomy and Diversion. J. Urol. 158:776-777, 1997

• Kalbhen, CL, Salomon, C.G., Dudiak, C.M., Olson, M.G., Flisak, ME, Flanigan, R.C.: Complications of Prostate Cryosurgery: CT findings in Three Patients. Accepted Abdominal Imaging, 23(4):442-5, 1998.

• Flanigan, R.C., Reda, D., Wasson, J., Bruskewicz, R.: five Year Outcomes of Surgical Resection and Watchful Waiting for Men with Moderately Symptomatic Benign Prostatic Hyperplasia. Results from a Department of Veterans Affair Cooperative Study. J. Urol. 160:12-17, 1998.

• Catalona, W.J., Partin, A.W., Slawin, K.M., Brawer, M.K., Flanigan, R.C., et al: Use of Percent Free Prostate Specific Antigen to Enhance Differentiation of Prostate Cancer from Benign Prostatic Disease: Results of a Prospective Multicenter Trial of 773 Men. JAMA. 279:1542-1547, 1998.

• Schroeder, L.E., Blumenstein, B.A., Flanigan, R.C., Borst, J.R., Crawford, E.D.: Phase II Evaluation of Doxorubicin/Vinblastine Combined with Inhibitors (Trifluoperazine/Verapamil) of P-Glycoprotein in Patients With Advanced Renal Carcinoma. Urol. Oncol. 3:94-98, 1997.

• Lewis, R., Coutee, J., Steinmuller, D., Hatch, D., Manion, S., Agrawal, R., Moel, D., Flanigan, R. Use of Cyclosporine Pharmokinetic Profiles in an Antibody Induction Protocol Reduces Acute Rejection Rates in Recipients of Primary Cadaveric Renal Allografts. Transplant Proc. 29(1-2):294-5, 1997.

• Dougherty, S., Manion, S., Walloch, J., Flanigan, R.C. Et al: Intratumor Heterogeneity of Early Stage (Stage A2) Prostate Adenocarcinomas: I. Evaluation of Archival Tumors by Flow Cytometry. Cytometry 27:126-131, 1997.

• Jin, J.K., Walloch, J., Flanigan, R.C., Shankey, TV: Intratumor Heterogeneity of Early (Stage A2) Prostate Adenocarcinomas II. Evaluation of Archival Tumors by Image Analysis. Cytometry 27:132-140, 1997.

• Flanigan, R.C. Role of Surgery in Patients with Metastatic Renal Cell Carcinoma (Review). Sem.Urol.Oncol. 14(4):227-9, 1996.

• Elias, L., Blumenstein, B.A., Kish, J., Flanigan, R.C., Wade, J.L., Lowe, B.A., Goodwin, J.W., Crawford, E.D.: Phase II Trial of Interferon and 5-Fluorouranl in Advanced Renal Cell Carcinoma. Cancer, 78:1085-1088, 1996.

• Flanigan, R.C., McKay, T.C., Olson, M., Shankey, TV, Pyle, J., Waters, W.B.: Limited Efficacy of Preoperative Computed Tomographic Scanning for the Evaluation of Lymph Node Metastases on Patients Before Radical Prostatectomy. Urology. 48:428, 1996.

• Challenger, R.J., Dougherty, W.S., Flisak, ME, and Flanigan, R.C.: Left Renal Vein Hypertension: A Cause of Persistent Gross Hematuria. Urology, 48:468-472, 1996.

• Sarosdy, M., Schellhammer, P.F., Lamm, D.L., Graham, S.D., Flanigan, R.C., Crawford, E.D.: Oral Bropiramine Immunotherapy in Carcinoma In Situ of the Bladder. Results of a Phase III Trial. Urology. 48(1):21-7, 1996.

• Griffin, J.H., Flanigan, R.C.: Nephron-Sparing Surgery for Renal Cell Carcinoma. Techniques in Urology, 2:43-47, 1996.

• Flanigan, R.C.: What's New in Urology. J. Am. Coll. of Surg., 182:185-190, 1996.

• Salomon, C.G., Dudiak, C.M., Pyle, J.M., Wheeler, J.S., Waters, W.B., Flanigan, R.C.: Transrectal Ultrasound of the Prostate Bed After Collagen Injection. J. Comput. Assist. Tomog., 279-282, 1996.

• Lindgren, B.W., Posniak, H.V., Demos, T., Marsan, R., Kostro, B., Calvert, D., Dougherty, W.S., Hatch, D.A., Flanigan, R.C., and Lewis, R.M.: Renal Computed Tomography with 3-Dimensional Angiography and Simultaneous Measurement of Plasma Contrast Clearance Reduce Invasiveness and Cost of Evaluating Living Renal Donor Candidates. Transplantation 61:219-223, 1996.

Back to top

Selected Book Chapters/Monographs:

• Kim, F., Nicholson, B. and Flanigan, R.C.:Open Prostatectomy for Benign Disease in Advanced Therapy of Prostate Disease, Ed. Ian Thompson, B.C. Decker, Inc. 2000

• Flanigan, R.C. and Kim, F.:Neoplastic Disease of the Pelvis, Ureter, Bladder and Urethra, Textbook of Neprology, Ed. 4th Edition Williams and Wilkins, Maryland 2000

• Flanigan, R.C. And Kim, F.:Prostate Cancer Localized T1,T2 in the 5 Minute Urology Consult, 1st Edition, Ed. L. Gomella, Williams and Wilkins, Maryland 2000

• Flanigan, R.C. And Kim, F.:Bladder Cancer Invasive T2, T3, T4 in the 5 Minute Urology Consult, 1st Edition, Ed. Ed L. Gomella, Williams and Wilkins, 2000

• Flanigan, R.C.:Renal Mass in Surgical Decision Making, Ed. Norton, L.W., Steigmann, G., Eiseman, B., W.B. Saunders, Philadelphia 1999.

• Flanigan, R.C. And Kim, F.:Renal and Ureteric Tumors in Principles of Urology, Ed. Weiss, George, and O'Reilly Mosky, 1999

• Flanigan, R.C. And Pierpaoli, S.: Follow-Up Care in Prostate Cancer in Surgery of the Prostate, Ed. Resnick, M., Thompson, I., pp. 197-205, Churchill, New York, 1998.

• Flanigan, R.C., Kim, F.,: Evaluation of Benign and Malignant Adrenal Masses in Atlas of Clin. Urology, Ed. Novick, A.C. Current Med., Inc., Philadelphia, 1998.

• Kim, F.J., Flanigan, R.C.: Renal Surgery Potpourri and Tricks of the Trade: Open Nephrostomy, Open Renal Biopsy, Perinephric Abscess and Uper Pole Nephrectomy in Atlas of the Urol. Clinics of North America,Vol. 6 No. l,1998. W.B. Saunders, Philadelphia.

• Flanigan, R.C.: Seminal Vesiculectomy in Atlas of Urol. Surgery, Ed. Hinman, F., Jr., W.B. Saunders, Philadelphia, 1998, P. 481-484.

• Flanigan, Robert C.: Seminal Vesiculectomy in Atlas of Urologic Surgery, Ed. Hinman, Jr., F., pp. 481-484, W.B. Saunders, Philadelphia, 1998.

• Flanigan, R.C. And Shankey, T.V.: The Natural History of Human Prostate Cancer in Principles & Practice of Genitourinary Oncology. Eds. Rashwan, D., Scher, H.I., Leibel, S.A., And Lange. P., Ch. 44, pp. TBD, 1997.

• Flanigan, R.C.: Urethrectomy in Urologic Oncology, Ed. Oesterling, J.E., Richie, J., pp. 579-588, W.B. Saunders Co., Philadelphia, 1997.

• Flanigan, R.C.: Advances in Immunotherapy and Chemotherapy for Renal Cell Carcinoma. Urology Annual 1997, Ed. Rous, S., Ch. 7, pp. 95-105. Blackwell Science.

• Flanigan, R.C.: T2c, M1b Carcinoma of the prostate in Tumor Board Case Management, Ed. Winchester, D.P., Brenna, M.F., et al. Lippincott Raven, Philadelphia 109:541-545, 1997.

• Flanigan, R.C. And Manion, S.P.: Treatment of Stage D2 Prostate Cancer in Surgical and Medical Management of Prostate Cancer. Ed. Middleton, R. Igaku-Shorn Med. Publishers, pp. 110-121, 1996.

• Flanigan, R.C.: Role of Surgery in Patients with Metastatic Renal Cell Carcinoma. Seminars in Urologic Oncology, 14:, 1996.

Back to top

Selected Presentations:

• Diagnosis and Therapy of Prostate Cancer; Compass Med. Education Network Adv. in Int. Med. (Chicago, IL); Nov. 6, 1999.

• A Review of New Concepts, Diagnosis, Prevention and Management of CAP; Chicago Urologic Society; Nov. 3, 1999.

• Residual Disease after Cytokine Therapy in RCC, First Intern; Kidney Cancer Symp. (Chicago, IL); Oct. 1, 1999.

• Management of Renal Cancer; Jefferson Urol. Meeting; October 1999.

• Current Management of Renal Cell Carcinoma; N.C. Sec. Res. Educ. Conf.; Sept. 22, 1999.

• Renal Cell Carcinoma and the Incidental Renal Mass:An update; Great Lakes Urol. Seminar (Detroit, MI); March 13, 1999.

• Moderator, Huggins Resident Essay Contest (Chicago, IL); Urological Society; Jan. 13, 1999.

• Screening for Prostate Cancer; Early Prostate Cancer (Miami, FL); Jan. 3, 1999.

• Neoadjuvant Hormonal Therapy Prior to Radical Prostatectomy; Chicago Urological Society; Dec. 2, 1998.

• Telomerase Activity and Length in PIN; Society of Pelvic Surgeons (Sarasota, FL); Nov. 13-15, 1998.

• Does the Choice of Anesthetic Technique Affect Recovery of Bowel Function After Radical Prostatectomy; Society of Pelvic Surgeons (Sarasota, FL); Nov. 13-15, 1998.

• Use of the Percentage of Free PSA in the Diagnosis of Prostate Cancer; North Central AUA (Amelia Island, FL); Oct. 17, 1998.

• Renal Cell Carcinoma - Staging/Prognostic Factors/ Diagnosis; Annual Convention, National Kidney Cancer Assoc. (Chicago, IL); July 17-19, 1998.

• BCG: Monthly Maintenance; Am. Assn. Of GU Surg.; April 18, 1998.

• Rec. For Staging and F/U of Bladder Cancer; Chicago Urol. Soc.; March 4, 1998.

• Renal Cancer Overview; Plenary Session, SWOG; February 1998.

• Reconstructive Surgery for Iatrogenic Injuries; Chicago Urologic Society; Jan. 4, 1998.

• Prostate Cancer: Developing a Strategy for the Next Two Decades; Early Prostate Cancer Workshop (Miami, FL); Jan. 3-4, 1998.
• BCG: Is Monthly Maintenance and Options for TCC of the Bladder; Amer. Urol. Assn. (San Diego, CA); Nov. 10, 1997.

• Obstructive Uropathy; The Natl. Center for Adv. of Medical Education; (Chicago, IL); Nov. 10, 1997.

• Lecturer, Stanford Urological Meeting, Renal Cell Cancer (Maui, HI);.Oct. 21-23, 1997.

• Visiting Professor, Kentucky Medical Assoc. and Kentucky Urological Society; Sept. 15-17, 1997.

• Urologic Seminar: An Update on RCC and Current Issues in the Treatment of Superficial TCC; Univ. of Albama (Birmingham, AL) ; June 24-27, 1997.

• Program Director, Chicago Prostate Cancer Shootout; June 20-21, 1997.

• Moderator, Chicago Urology Resident Debate; May 15, 1997.

• Enterstomal Therapy Nursing Education Program; April 1997.

• The Natural History of Prostate Cancer and Watchful Waiting in Prostate Cancer; International Prostate Cancer Symposium, Emory Univ. (Atlanta, GA); April 18-19, 1997.

• Renal Cell Carcinoma - Overview; Nephron Spariing Surgery; Surgical Management of Advanced RCC; Upper Tract TCC; Continent Diversions - Patient Selection, Techniques and Results. Urology Update 1997, West Virginia University; March 7-8, 1997.

• Program Director, Urology Course; Chicago Medical Society; Feb. 7-9, 1997.

• Treatment of Metastatic Renal Cell Carcinoma; State of Art Lecture: Kimbrough Urological Seminar; Dec. 2-6, 1996.

• Urol-Oncology-Adjuvant Therapy for RCC and Partial Nephrectomy in RCC (New Orleans, LA); Nov. 21-23, 1996.

• Moderator, American College of Surgeons - Urology Cine Clinic (San Francisco, CA); Oct. 8, 1996.

• Role of Nephrectomy in Metastatic Renal Cell Carcinoma; National Kidney Cancer Assn. Meeting; July 18, 1996.

• Advancements in Urologic Oncology; Louisiana State Urological Society (Shreveport, LA); June 14-16, 1996.

• Point/Counterpoint Nephron-Sparing Surgery in Renal Cancer; Amer. Urol. Assn. Meeting Plenary Session (Orlando, FL); May 6, 1996.

• Moderator, Genital Neoplasia and Physiology; Amer. Urol. Assn. Meeting (Orlando, FL); May 7, 1996.

• Current Concepts on the Therapy of Renal Cell Carcinoma; Honored Guest, SE Section, Amer. Urol. Assn. Meeting, (San Juan, PR); April 14, 1996.

• Faculty, James H. McDonald Urological Seminar (Scottsdale, AZ); March 15-17, 1996.

• Faculty, International Urology Preceptorship Program (Denver, CO); March 10-15, 1996.

• Prostate Cancer; Chicago Medical Society Annual Meeting; Feb. 2, 1996.

• Controversies in Prostate Cancer Treatment; Midwest Clin. Conf./Amer. Cancer Society; Feb. 1, 1996.

Back to top

Selected Research Initiatives:

• Soy Isoflavones in Prostate Cancer and PIN; Archer Daniels Midland; 1999-2001 ($290,000).

• Max and Depriv. Vrs. LHRH Agonist Alone in Brachytherapy; Schering-Plough; 1999-2000 ($150,000).

• Prostate Cancer Prevention Trial; Southwest Oncology Group-NIH; 1993-2004 ($150,000).

• Urologic Cancer Outreach Program; NCI (NIH); 1988-2001 ($350,000).

• Emotional Expression and Psychological Adjustment to Prostate Cancer: A Brief Intervention for Patients and Their Partners; P.I. Zakowski, S. RCF Scientific Participant; 1999 ($4,000).

• Interferon in the Treatment of Advanced Prostate Cancer; Schering-Plough; 1990-1994 ($7,000).

• Bropirimine for Prostate Cancer; Upjohn; 1995-1996 ($33,000).

• Free vs. Total PSA in Men with Total PSA 4-10 ng/ml; Hybritech Corp.; 1995-1997 ($150,000).

• Liarizal for Early Stage Prostate Cancer; Janssen Phram; 1997-1998 ($100,000).

• Bropirimine for Bladder Cancer; Upjohn; 1996-1997 ($82,000).

Back to top

More information on Dr. Flanigan

Back to main Clinical Faculty page